Opko Health Inc. (NASDAQ:OPK) CEO Buys $223,000.00 in Stock

Share on StockTwits

Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 100,000 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The shares were acquired at an average price of $2.23 per share, for a total transaction of $223,000.00. Following the purchase, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $6,843,760.73. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Tuesday, July 2nd, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The shares were acquired at an average price of $2.42 per share, for a total transaction of $121,000.00.
  • On Tuesday, June 25th, Phillip Md Et Al Frost acquired 100,000 shares of Opko Health stock. The shares were acquired at an average price of $2.01 per share, for a total transaction of $201,000.00.
  • On Thursday, June 20th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The shares were acquired at an average price of $2.04 per share, for a total transaction of $102,000.00.
  • On Tuesday, June 18th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The shares were acquired at an average price of $2.02 per share, for a total transaction of $101,000.00.
  • On Thursday, June 13th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The shares were acquired at an average price of $1.92 per share, for a total transaction of $96,000.00.
  • On Tuesday, June 11th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The shares were acquired at an average price of $1.87 per share, for a total transaction of $93,500.00.
  • On Friday, June 7th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The shares were acquired at an average price of $1.87 per share, for a total transaction of $93,500.00.
  • On Wednesday, June 5th, Phillip Md Et Al Frost acquired 150,000 shares of Opko Health stock. The shares were acquired at an average price of $1.92 per share, for a total transaction of $288,000.00.
  • On Thursday, May 30th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The shares were acquired at an average price of $1.86 per share, for a total transaction of $93,000.00.
  • On Tuesday, May 28th, Phillip Md Et Al Frost acquired 200,000 shares of Opko Health stock. The shares were acquired at an average price of $1.90 per share, for a total transaction of $380,000.00.

OPK opened at $2.14 on Friday. The firm has a market capitalization of $1.39 billion, a price-to-earnings ratio of -8.56 and a beta of 2.14. Opko Health Inc. has a fifty-two week low of $1.73 and a fifty-two week high of $6.40. The stock’s 50-day simple moving average is $2.05. The company has a current ratio of 1.10, a quick ratio of 0.99 and a debt-to-equity ratio of 0.13.

Opko Health (NASDAQ:OPK) last posted its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.08). Opko Health had a negative return on equity of 9.86% and a negative net margin of 19.92%. The firm had revenue of $222.50 million during the quarter, compared to the consensus estimate of $241.27 million. During the same quarter last year, the company posted ($0.08) EPS. Opko Health’s revenue for the quarter was down 12.7% on a year-over-year basis. Equities analysts anticipate that Opko Health Inc. will post -0.42 EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Amundi Pioneer Asset Management Inc. bought a new position in Opko Health in the 1st quarter worth about $67,000. B. Riley Wealth Management Inc. bought a new position in Opko Health in the 1st quarter worth about $39,000. Nordea Investment Management AB bought a new position in Opko Health in the 1st quarter worth about $820,000. Marshall Wace North America L.P. bought a new position in Opko Health in the 1st quarter worth about $410,000. Finally, Marshall Wace LLP grew its position in Opko Health by 3,541.3% in the 1st quarter. Marshall Wace LLP now owns 1,452,176 shares of the biotechnology company’s stock worth $3,099,000 after purchasing an additional 1,412,295 shares during the last quarter. Hedge funds and other institutional investors own 25.35% of the company’s stock.

Several equities research analysts recently weighed in on the stock. Zacks Investment Research lowered shares of German American Bancorp. from a “buy” rating to a “hold” rating in a research note on Tuesday, April 30th. ValuEngine lowered shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. Opko Health presently has a consensus rating of “Buy” and an average target price of $9.25.

About Opko Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

See Also: Momentum Indicators

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.